NIH agreement to accelerate therapies for CLL

[Guest guest]

" The National Institutes of Health announced an agreement

with two non-profit organizations to accelerate the

development of potential clinical therapies for rare blood

cancers.

The agreement is among the University of Kansas Medical

Center, Kansas City, The Leukemia & Lymphoma Society (LLS),

the NIH Therapeutics for Rare and Neglected Diseases (TRND)

program and the Hematology Branch within the National Heart,

Lung and Blood Institute. "

Source: http://www.nih.gov/news/health/may2011/nhgri-25.htm

CLL CANADA

http://cllcanada.ca